TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9820298

Group type: EXPERIMENTAL
Intervention: Computer-generated dosing (n=137)
Number of subjects: 285

Group type: COMPARATOR
Intervention: Traditional dosing (n=148)
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Computer-generated dosing (stabilisation patients)
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Computer-generated dosing (stable patients)
Number of subjects: 285
Study: 8548110

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amiodarone (low doses)
Number of subjects: 0
Study: 2611359

Group type: EXPERIMENTAL
Intervention: Oral administration of cyclosporine
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Intravenous administration of cyclosporine
Number of subjects: 8
Study: 319730

Group type: EXPERIMENTAL
Intervention: 30% DMSO
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.1%
Number of subjects: 0

Group type: COMPARATOR
Intervention: 90% DMSO
Number of subjects: 0

Group type: COMPARATOR
Intervention: 100% DMSO
Number of subjects: 0

Group type: COMPARATOR
Intervention: 50% to 70% DMSO
Number of subjects: 0
Study: 29380956

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Polyphenol blend (PPB)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Caspase 8
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Caspase 3 and Caspase 9
Number of subjects: 38
Study: 26383586

Group type: EXPERIMENTAL
Intervention: Video-augmented verbal feedback
Number of subjects: 0

Group type: COMPARATOR
Intervention: Verbal only feedback
Number of subjects: 0
Study: 25421363

Group type: EXPERIMENTAL
Intervention: Fatigue self-management (FSM) intervention, which included two sessions of a nurse-delivered protocol and a self-help book.
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Fatigue self-management (FSM) intervention
Number of subjects: 73

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 73
Study: 23292674

Group type: EXPERIMENTAL
Intervention: Physiomesh in IHR
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Physiomesh in VHR
Number of subjects: 100
Study: 20813346

Group type: EXPERIMENTAL
Intervention: Azithromycin ophthalmic solution 1%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Moxifloxacin ophthalmic solution 0.5%
Number of subjects: 0
Study: 18802150

Group type: COMPARATOR
Intervention: VACA (vincristine, dactinomycin, cyclophosphamide, doxorubicin)
Number of subjects: 647

Group type: COMPARATOR
Intervention: EVAIA (vincristine, dactinomycin, ifosfamide, doxorubicin, etoposide)
Number of subjects: 647
Study: 15652870

Group type: EXPERIMENTAL
Intervention: Dorsolateral region in boys with autism
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control subjects (normal boys)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dorsolateral and medial frontal regions in boys with autism aged 2 to 5 years
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Precentral gyrus and orbital cortex in boys with autism
Number of subjects: 0
Study: 12847482

Group type: EXPERIMENTAL
Intervention: FP 400 microg twice a day plus SALM 50 microg twice a day (FP 400 + SALM)
Number of subjects: 56

Group type: COMPARATOR
Intervention: FP 200 microg twice a day (FP400)
Number of subjects: 56

Group type: COMPARATOR
Intervention: FP 1000 microg twice a day (FP1000)
Number of subjects: 56
Study: 10502079

Group type: EXPERIMENTAL
Intervention: 5 min of cycle ergometer exercise at 90% VO2(max) (AO)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Standard circuit-training routine (CT)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 2 h cycle ergometer exercise at 60% VO2(max) (Long)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Seated for 5 h (Control)
Number of subjects: 8
Study: 8759045

Group type: EXPERIMENTAL
Intervention: Freedom to volunteer or withhold information
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Accuracy incentive
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monitoring effectiveness
Number of subjects: 0
Study: 1714709

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (enoxaparin) 40.6 mg subcutaneously once daily
Number of subjects: 246

Group type: COMPARATOR
Intervention: Dextran 70 (standard regimen)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (enoxaparin)
Number of subjects: 246
Study: 7082534

Group type: EXPERIMENTAL
Intervention: 0.4 mg sublingual buprenorphine
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 0.8 mg sublingual buprenorphine
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 6489425

Group type: EXPERIMENTAL
Intervention: Atenolol 62.5 micrograms/kg i.v.
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Pindolol 7.5 micrograms/kg i.v.
Number of subjects: 26
Study: 30806807

Group type: EXPERIMENTAL
Intervention: Local application of MMR vaccine after surgery
Number of subjects: 31

Group type: COMPARATOR
Intervention: Surgical excision alone (Control)
Number of subjects: 31
Study: 30371183

Group type: EXPERIMENTAL
Intervention: HAS-BLED score
Number of subjects: 3550

Group type: COMPARATOR
Intervention: GARFIELD-AF score
Number of subjects: 3550
Study: 26501882

Group type: EXPERIMENTAL
Intervention: Consensus-modified criteria (CM-2012)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Modified tissue orientation protocol
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional tissue-handling protocol (CP)
Number of subjects: 100
Study: 24630163

Group type: EXPERIMENTAL
Intervention: Whiplash patients
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control participants
Number of subjects: 60
Study: 22923328

Group type: EXPERIMENTAL
Intervention: Drinkable solution of 70 mg/100 mL alendronate
Number of subjects: 128

Group type: COMPARATOR
Intervention: Tablets of alendronate
Number of subjects: 128
Study: 20599461

Group type: EXPERIMENTAL
Intervention: Medications for bipolar disorder
Number of subjects: 152
Study: 17662438

Group type: EXPERIMENTAL
Intervention: Intracameral mydriatics (150 muL of phenylephrine 1.5% and lidocaine 1%)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Conventional topical mydriatics and intracameral lidocaine
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Intracameral mydriatics
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Corneal edema
Number of subjects: 22
Study: 16238797

Group type: EXPERIMENTAL
Intervention: Inhaled steroids during allergen exposure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo treatment during allergen exposure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhaled steroids
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-dose allergen exposure
Number of subjects: 0
Study: 12915593

Group type: EXPERIMENTAL
Intervention: CHOP plus G‐CSF
Number of subjects: 389

Group type: COMPARATOR
Intervention: CHOP
Number of subjects: 389
Study: 10202647

Group type: EXPERIMENTAL
Intervention: PE + CBT
Number of subjects: 56

Group type: COMPARATOR
Intervention: PE-alone
Number of subjects: 56
Study: 8727431

Group type: EXPERIMENTAL
Intervention: Tidal volume (VT) increased to 12-14 ml/kg for 30 min
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Tidal volume (VT) decreased to 6-8 ml/kg for 30 min
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Tidal volume (VT) increased to 12-14 ml/kg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Tidal volume (VT) decreased to 6-8 ml/kg
Number of subjects: 15

Group type: COMPARATOR
Intervention: Comparison of PaCO2 levels
Number of subjects: 15
Study: 1985823

Group type: EXPERIMENTAL
Intervention: Progabide (PGB)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 6339999

Group type: EXPERIMENTAL
Intervention: Potassium canrenoate (200 mg/day for 21 days)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Spironolactone (200 mg/day for 21 days)
Number of subjects: 21
Study: 30867041

Group type: EXPERIMENTAL
Intervention: Profender® spot-on (emodepside 2.1% and praziquantel 8.6%) administered on days 0 and 14
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Profender® spot-on (emodepside 2.1% and praziquantel 8.6%)
Number of subjects: 16
Study: 27498023

Group type: EXPERIMENTAL
Intervention: Axitinib 5 mg twice per day (b.i.d.; n = 192)
Number of subjects: 288

Group type: COMPARATOR
Intervention: Sorafenib 400 mg b.i.d. (n = 96)
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Axitinib in patients with ECOG PS 0
Number of subjects: 288

Group type: COMPARATOR
Intervention: Sorafenib in patients with ECOG PS 0
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Axitinib in patients with ECOG PS 1
Number of subjects: 288

Group type: COMPARATOR
Intervention: Sorafenib in patients with ECOG PS 1
Number of subjects: 288
Study: 25833970

Group type: EXPERIMENTAL
Intervention: Lipid emulsion 1 (LE1; acid stable, 0.33 μm)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Lipid emulsion 2 (LE2; acid stable, 52 μm)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Lipid emulsion 3 (LE3; acid unstable, solid fat, 0.32 μm)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Lipid emulsion 4 (LE4; acid unstable, liquid fat, 0.38 μm)
Number of subjects: 18
Study: 24938562

Group type: EXPERIMENTAL
Intervention: selumetinib, 75 mg orally twice daily on a continual basis (n=50)
Number of subjects: 120

Group type: COMPARATOR
Intervention: chemotherapy (temozolomide, 150 mg/m2 orally daily for 5 of every 28 days, or dacarbazine, 1000 mg/m2 intravenously every 21 days) (n=51)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: selumetinib
Number of subjects: 120

Group type: COMPARATOR
Intervention: chemotherapy
Number of subjects: 120
Study: 23136545

Group type: EXPERIMENTAL
Intervention: Erythropoietin treatment
Number of subjects: 104
Study: 19489810

Group type: EXPERIMENTAL
Intervention: Ambient room
Number of subjects: 62

Group type: COMPARATOR
Intervention: Standard room
Number of subjects: 62
Study: 18091308

Group type: EXPERIMENTAL
Intervention: Aniseikonia Inspector Version 1
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Aniseikonia Inspector Version 2
Number of subjects: 27
Study: 15003736

Group type: EXPERIMENTAL
Intervention: Low Carbohydrate Diet (LCH)
Number of subjects: 34

Group type: COMPARATOR
Intervention: High Carbohydrate Diet (HCH)
Number of subjects: 34
Study: 12170275

Group type: EXPERIMENTAL
Intervention: Education about NRL allergies and introduction of powder-free NRL gloves
Number of subjects: 3000000

Group type: EXPERIMENTAL
Intervention: Purchase of powder-free NRL examination gloves
Number of subjects: 3000000

Group type: EXPERIMENTAL
Intervention: Purchase of powder-free NRL sterile gloves
Number of subjects: 3000000

Group type: EXPERIMENTAL
Intervention: Intervention strategies including education and regulations
Number of subjects: 3000000
Study: 10483952

Group type: EXPERIMENTAL
Intervention: Lower extremity arterial disease (LEAD) defined as an ankle/arm systolic blood pressure ratio of 0.90 or less.
Number of subjects: 405

Group type: COMPARATOR
Intervention: No lower extremity arterial disease (non-LEAD)
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Lower extremity arterial disease (LEAD)
Number of subjects: 405
Study: 8963892

Group type: EXPERIMENTAL
Intervention: Baseline tilt testing for 45 minutes
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Isoprenaline infusion
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Edrophonium bolus (10 mg)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Recurrent syncope
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Significant structural heart disease (SHD) or sudden diminished consciousness (SDC)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Age below or above 50 years
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Combination of factors (age, SHD, SDC, recurrent syncope)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Additional yield of isoprenaline
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Additional yield of edrophonium
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Second drug required for positive result
Number of subjects: 145
Study: 1875966

Group type: EXPERIMENTAL
Intervention: Paracentesis plus intravenous albumin
Number of subjects: 89

Group type: COMPARATOR
Intervention: LeVeen peritoneovenous shunt
Number of subjects: 89
Study: 6617274

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA) 20 mg three times daily
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 30068518

Group type: EXPERIMENTAL
Intervention: Dietary intervention focused on plant foods, low glycemic load, low in saturated fats and alcohol
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Physical activity (PA) intervention combining daily moderate intensity activities and one weekly supervised session of more strenuous activity
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Both dietary and physical activity interventions
Number of subjects: 226

Group type: COMPARATOR
Intervention: General recommendations (control group)
Number of subjects: 226
Study: 29575010

Group type: EXPERIMENTAL
Intervention: Combined diabetes peer support and usual care
Number of subjects: 1121

Group type: EXPERIMENTAL
Intervention: One-to-one diabetes peer support and usual care
Number of subjects: 1121

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1121
Study: 27580228

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Release Program (6 weeks)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Waitlist Control Group
Number of subjects: 50
Study: 24488447

Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 122

Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 122
Study: 23776460

Group type: EXPERIMENTAL
Intervention: Bilateral STN‐DBS (on-stimulation)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Bilateral STN‐DBS (off-stimulation)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 13
Study: 20934654

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 347
Study: 18087207

Group type: EXPERIMENTAL
Intervention: Systemic Family Therapy (SFT) associated with routine psychiatric treatment
Number of subjects: 40

Group type: COMPARATOR
Intervention: Routine psychiatric treatment alone
Number of subjects: 40
Study: 15673749

Group type: EXPERIMENTAL
Intervention: Mefloquine (M group)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Quinine plus Sulphalene-Pyrimethamine (QSP group)
Number of subjects: 187
Study: 12544868

Group type: EXPERIMENTAL
Intervention: Basiliximab (20 mg before transplantation and 20 mg on day 4)
Number of subjects: 123
Study: 10370315

Group type: EXPERIMENTAL
Intervention: Additional nonspecific detoxication (AND) applied for prophylaxis starting from the burn shock period
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Additional nonspecific detoxication (AND) applied after sepsis has begun
Number of subjects: 176

Group type: COMPARATOR
Intervention: Control group (no AND application)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Overall mortality
Number of subjects: 176
Study: 8736467

Group type: EXPERIMENTAL
Intervention: Loading doses of imipramine hydrochloride on two consecutive days
Number of subjects: 16

Group type: COMPARATOR
Intervention: Conventional gradually escalating dose regimen of imipramine
Number of subjects: 16
Study: 1421930

Group type: EXPERIMENTAL
Intervention: Lactose-containing diet (6 g lactose/kg body weight/d)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Lactose-containing diet
Number of subjects: 33

Group type: COMPARATOR
Intervention: Tests of stool reducing substances and lactose breath hydrogen test (LHBT)
Number of subjects: 33
Study: 3900837

Group type: EXPERIMENTAL
Intervention: Intravenous ceforanide
Number of subjects: 64

Group type: COMPARATOR
Intervention: Intrauterine ceforanide
Number of subjects: 64
Study: 31028596

Group type: EXPERIMENTAL
Intervention: Intervention group with medication review by a pharmacist
Number of subjects: 0
Study: 30515483

Group type: EXPERIMENTAL
Intervention: Endodontic retreatment (Endo group)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Implant treatment (Implant group)
Number of subjects: 20
Study: 26877214

Group type: EXPERIMENTAL
Intervention: Anger mood condition
Number of subjects: 190

Group type: COMPARATOR
Intervention: Neutral mood condition
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Both conditions
Number of subjects: 190
Study: 23588487

Group type: EXPERIMENTAL
Intervention: Static stretching (6 lower-body stretches for three 30-second repetitions)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Nonstretching condition (sat still for 10 minutes)
Number of subjects: 10
Study: 22452652

Group type: COMPARATOR
Intervention: CO2 insufflation during colonoscopy
Number of subjects: 21

Group type: COMPARATOR
Intervention: CO2 insufflation during ERCP
Number of subjects: 21

Group type: COMPARATOR
Intervention: CO2 insufflation during DBE
Number of subjects: 21

Group type: COMPARATOR
Intervention: CO2 insufflation during oesophagus/stomach endoscopic submucosal dissection
Number of subjects: 21

Group type: COMPARATOR
Intervention: CO2 insufflation
Number of subjects: 21
Study: 21387805

Group type: EXPERIMENTAL
Intervention: Visual stimulation (black and white checkerboard pattern reversal)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Visual stimulation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no visual stimulation)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study: 18755343

Group type: EXPERIMENTAL
Intervention: Stent implantation
Number of subjects: 123

Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 123
Study: 15948680

Group type: EXPERIMENTAL
Intervention: HF‐DDS graft (test)
Number of subjects: 25

Group type: COMPARATOR
Intervention: GA (control)
Number of subjects: 25
Study: 12807373

Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 113
Study: 10551065

Group type: EXPERIMENTAL
Intervention: Demineralized laminar bone sheets (experimental)
Number of subjects: 7

Group type: COMPARATOR
Intervention: GTAM membranes (control)
Number of subjects: 7
Study: 8544272

Group type: EXPERIMENTAL
Intervention: Histamine2-receptor antagonists
Number of subjects: 63

Group type: COMPARATOR
Intervention: Antacids
Number of subjects: 63

Group type: COMPARATOR
Intervention: Sucralfate
Number of subjects: 63
Study: 8220395

Group type: EXPERIMENTAL
Intervention: 2.4-g arginine/lysine supplement
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 1.85-g ornithine/tyrosine supplement
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 20-g BovrilR drink
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 3114333

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 10
Study: 29435826

Group type: EXPERIMENTAL
Intervention: Bovine lactoferrin (bLf) application after surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Classical surgical treatment
Number of subjects: 0
Study: 29489098

Group type: EXPERIMENTAL
Intervention: Infusion of levosimendan started intraoperatively after induction of anesthesia, a loading dose of 6 mg/kg with subsequent injection of a dose of 0.1 μg/kg/min for 24 hours.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Bolus of levosimendan 24 μg/kg injected 15 min before aortic clamping.
Number of subjects: 40
Study: 26099761

Group type: EXPERIMENTAL
Intervention: Neostigmine 2.5 mg with glycopyrrolate 0.4 mg
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 24290737

Group type: EXPERIMENTAL
Intervention: Gabapentin enacarbil 1200 mg
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Gabapentin enacarbil 6000 mg
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52

Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg (active control)
Number of subjects: 52
Study: 21453665

Group type: EXPERIMENTAL
Intervention: 3D biomodel‐assisted reconstruction
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Freehand constructs
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 3D biomodel‐assisted bending
Number of subjects: 20

Group type: COMPARATOR
Intervention: Freehand technique
Number of subjects: 20
Study: 20183654

Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy‐Adolescent Skills Training (IPT‐AST)
Number of subjects: 41

Group type: COMPARATOR
Intervention: School Counseling (SC)
Number of subjects: 41
Study: 16734607

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 14765705

Group type: EXPERIMENTAL
Intervention: EMG-EL
Number of subjects: 8
Study: 11705721

Group type: EXPERIMENTAL
Intervention: Visual search analog of latent inhibition (LI)
Number of subjects: 228
Study: 10401195

Group type: EXPERIMENTAL
Intervention: Antiepileptic drugs (AED) alone
Number of subjects: 68

Group type: COMPARATOR
Intervention: Antitubercular therapy and albendazole (ATB + Alb) in addition to AED
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Whole group (n = 60)
Number of subjects: 68
Study: 7852876

Group type: EXPERIMENTAL
Intervention: Antheor caval filter
Number of subjects: 300
Study: 2803893

Group type: EXPERIMENTAL
Intervention: Supplementary oxygen
Number of subjects: 30

Group type: COMPARATOR
Intervention: Room air (Control)
Number of subjects: 30
Study: 1095511

Group type: EXPERIMENTAL
Intervention: Aprotininum (Trasylol) 200,000 KIE infusion every 6 hours during acute alcohol withdrawal
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 30788869

Group type: EXPERIMENTAL
Intervention: Premature ejaculation desensitisation therapy combined with 30 mg dapoxetine hydrochloride (DTCD group)
Number of subjects: 99

Group type: COMPARATOR
Intervention: 30 mg dapoxetine hydrochloride only (DO group)
Number of subjects: 99
Study: 27864616

Group type: EXPERIMENTAL
Intervention: Cyanoacrylate glue (1 ml of butyl‐2‐cyanoacrylate tissue glue, Glubran®)
Number of subjects: 302

Group type: COMPARATOR
Intervention: Absorbable sutures (polyglycolic acid sutures, Dexon®)
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Cyanoacrylate glue
Number of subjects: 302

Group type: COMPARATOR
Intervention: Absorbable sutures
Number of subjects: 302